Key facts
- This page summarizes Alexander L. Cappello's Form 4 filing for NAVIDEA BIOPHARMACEUTICALS, INC..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Nov 2022, 15:10.
Alexander L. Cappello - 30 Nov 2022 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 30 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Nov 2022, 15:10:20 UTC
- Prior SEC filing
- 01 Nov 2022
- Next SEC filing
- 27 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Erika L. Eves for Alexander L. Cappello, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alexander L. Cappello filed Form 4 for NAVIDEA BIOPHARMACEUTICALS, INC. on 30 Nov 2022.
Change
- Previous filing in this sequence was filed on 01 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAVB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,250
- Change %
- +1.9%
- Price
- $0.000000
- Shares after
- 67,727
- Date
- 30 Nov 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees.
Footnote F2
Issuance deferred at the request of the Reporting Person.